Integration of Huntleigh proceeding as planned

Integration of Huntleigh proceeding as planned

The previously announced plan for a rapid and effective integration of Huntleigh
into Getinge's Extended Care business area is proceeding as planned. During the
third quarter, a decision was taken to discontinue Huntleigh's production unit
for hospital beds in Wednesbury, United Kingdom. Manufacturing in this
production unit, which has approximately 360 employees, will be transferred to
Extended Care's production unit in Poznan, Poland. 

During the period, it was also decided to discontinue production at the unit in
Eatontown, USA. Manufacturing in this production unit will also be transferred
to Poznan, Poland, where similar manufacturing operations are already being
conducted. The closure of the operation in the United States will affect about
125 employees. In addition to the above activities, decisions were made during
the quarter to coordinate Extended Care's and Huntleigh's sales companies in
France, Belgium, Canada and the Netherlands. 

The cost of the restructuring and integration measures that were decided and
implemented during the period will be charged against earnings for the third
quarter of 2007 in an amount of about SEK 110 million. For the current year, it
continues to be estimated that the integration costs will amount to SEK 250-260
million. As before, the costs for finalizing the planned integration are
estimated to total approximately SEK 400 million and, in all essential respects,
the integration will be completed during 2008.

The savings that are expected to result from the implemented and planned
measures will exceed SEK 300 million on an annual basis and become fully visible
during 2009/2010. For the current year, it is estimated that the savings will
amount to SEK 50-60 million.     



Getinge 9th October 2007 


Johan Malmquist
President


Getinge Internet address http://www.getingegroup.com

The information provided herein is such that Getinge AB can be obligated to
disclose pursuant to the Securities and Clearing Operations Act and/or the
Financial Instruments Trading Act.